Ando, K.; Sakamoto, S.; Saito, S.; Maimaiti, M.; Imamura, Y.; Sazuka, T.; Sato, N.; Komiya, A.; Anzai, N.; Ichikawa, T.
Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel. Cancers 2021, 13, 773.
https://doi.org/10.3390/cancers13040773
AMA Style
Ando K, Sakamoto S, Saito S, Maimaiti M, Imamura Y, Sazuka T, Sato N, Komiya A, Anzai N, Ichikawa T.
Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel. Cancers. 2021; 13(4):773.
https://doi.org/10.3390/cancers13040773
Chicago/Turabian Style
Ando, Keisuke, Shinichi Sakamoto, Shinpei Saito, Maihulan Maimaiti, Yusuke Imamura, Tomokazu Sazuka, Nobuo Sato, Akira Komiya, Naohiko Anzai, and Tomohiko Ichikawa.
2021. "Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel" Cancers 13, no. 4: 773.
https://doi.org/10.3390/cancers13040773
APA Style
Ando, K., Sakamoto, S., Saito, S., Maimaiti, M., Imamura, Y., Sazuka, T., Sato, N., Komiya, A., Anzai, N., & Ichikawa, T.
(2021). Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel. Cancers, 13(4), 773.
https://doi.org/10.3390/cancers13040773